India Must Move Beyond ‘Made in India’ to Designed, Innovated & Exported MedTech: Dr Jitendra Singh

He added that the convergence of MedTech, digital health, AI, and interoperable health data could reshape healthcare delivery and improve access across the country.

India’s MedTech growth story must now shift from manufacturing products to designing, innovating and exporting them globally, Union Minister Dr Jitendra Singh has said, while calling for deeper integration among medical technology, digital health, AI, and interoperable health data.

India’s MedTech market is projected to reach $20 Bn by 2030, creating an opportunity to expand its role beyond that of a large consumer market and manufacturing base.

Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science & Technology and Earth Sciences, said India has an opportunity to simultaneously advance healthcare innovation and make new technologies affordable and accessible.

“This is where India can lead with a distinctive model for the rest of the world. High quality, high technology and high impact – all at a cost that people can afford.” - Union Minister Dr Jitendra Singh said.

Calling for a shift in ambition, he said India must move from “Made in India” towards being “Designed, Innovated and Exported from India” in MedTech. He also highlighted the growing scale of India's digital health ecosystem.

“By August 2026, more than 96.43 crore Ayushman Bharat Health Accounts have been created, with over 5.47 lakh health facilities and over 10.50 lakh health care professionals registered under the Ayushman Bharat Digital Mission. The next step is to create and ensure that medical technologies integrate seamlessly with the digital ecosystem.”

He added that the convergence of MedTech, digital health, AI, and interoperable health data could reshape healthcare delivery and improve access across the country.

Manoj Joshi, Secretary, Department of Pharmaceuticals, said India needs a regulatory architecture suited to its own industrial and technological landscape.

He also indicated that future Production Linked Incentive schemes could place greater emphasis on domestic value addition, with existing beneficiaries expected to reach 40-45%

Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India, said MedTech Mitra, the ICMR-CDSCO initiative supported by NITI Aayog, has received more than 850 applications, signalling the need for additional platforms that can help innovators navigate regulatory and development challenges.

Stay tuned for more such updates on Digital Health News